Marcio Vinicius Ayres

Marcio Vinicius Ayres

Auto-generated profile, based on publicly available information

Marcio Vinicius Ayres

Hospital de Clínicas de Porto Alegre (HCPA), Rio Grande do Sul, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2026 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
BCBrendha Lang Camboim
Brendha Lang Camboim
BBBruna Silveira Bersagui
Bruna Silveira Bersagui
SASílvia Helena de Oliveira Almeida
Sílvia Helena de Oliveira Almeida
MAMárcio Vinícius Ayres
Márcio Vinícius Ayres
AMAndreas Sebastian Loureiro Mendez
Andreas Sebastian Loureiro Mendez
CGCássia Virginia Garcia
Cássia Virginia Garcia
Levothyroxine sodium (SLT4) is the sodium salt of the thyroid hormone thyroxine, being the first-choice replacement therapy in hypothyroid disease. Congenital hypothyroidism affects infants, and represents one of the most common preventable causes of intellectual disability worldwide. In Brazil and other countries, tablets are the only dosage form of SLT4 for oral use. Pediatric patients and adults unable to swallow require SLT4 extemporaneously prepared in the hospital's routine, which can compromise safety. On the other hand, oral SLT4 solutions are available in USA, Italy, Spain, and United Kingdom. The aim of this work was to develop a SLT4 oral liquid formulation and assess its stability during 63 days under 4 °C, 25 °C and 40 °C, comparing amber glass bottles and sachet packing. In the development stage, excipients were evaluated by data tools (STEP and PERA) and the most suitable for pediatric use were chosen. An HPLC method was developed and validated to analyze SLT4 content, and forced degradation outcomes were investigated through UPLC-MS. Every 7 days, pH, drug amount, visual aspect, organoleptic properties and microbiological content were analyzed. The SLT4 30 µg/mL oral solution showed adequate physical chemical and microbiological characteristics. It was stable for 63 days when stored both in sachet and amber glass bottles at 4 °C and 25 °C. Six major degradation products structures were proposed after stress testing evaluations. It was possible to obtain a simple STL4 oral solution, with pediatric-safe excipients and dosing flexibility, representing an alternative for hospital treatment of hypothyroidism.

19 May 2026 in Hospital Pharmacy
Verified
Journal Article
Closed access
BBBruna S. Bersagui
Bruna S. Bersagui
GOGabriela A. de Oliveira
Gabriela A. de Oliveira
BCBrendha L. Camboim
Brendha L. Camboim
SASílvia H. O. de Almeida
Sílvia H. O. de Almeida
MAMárcio V. Ayres
Márcio V. Ayres
CGCássia V. Garcia
Cássia V. Garcia
Purpose: Losartan potassium is an antihypertensive drug commercialized only as tablets. As an alternative to the hospital pediatric extemporaneous preparations, it was developed a sugar-free oral liquid formulation containing this drug (2.0 mg/mL) in order to allow the dose adjustment, accuracy and easy administration. Methodology: The stability of formulation was evaluated at room temperature (15-30°C), refrigerated (2-8°C) and oven (40°C), during 56 days in amber glass bottles (n = 3). A stability-indicating analytical method by high performance liquid chromatography (HPLC) was used for drug determination weekly. The acceptance criterion was between 95.0% and 105.0%. Organoleptic characteristics, pH, viscosity, and microbiological content were also evaluated. Results: All samples under room and refrigerated conditions kept their pH values and microbiological content in accordance during all the period tested. However, for those at room temperature, the drug amount, formulation appearance and viscosity were adequate until the 42nd day of analysis, indicating that this was the recommended beyond-use date for the proposed solution. Conclusion: A simple and economical solution was obtained with the advantage to be sugar-free, without the cariogenic effect, and without the disadvantages of pharmaceutical suspensions, contributing to pediatric patients during hospital treatments.

19 December 2025 in Drug Analytical Research
Verified
Journal Article
Open access
NONicolas Almeida Oschelski
Nicolas Almeida Oschelski
CVCarolina Rita Venturi
Carolina Rita Venturi
SASilvia Helena Oliveira de Almeida
Silvia Helena Oliveira de Almeida
MAMarcio Vinicius Ayres
Marcio Vinicius Ayres
MSMartin Steppe
Martin Steppe
Sirolimus (SRL) is an immunosuppressive macrolide widely used in transplant patients to prevent organ rejection. The development of an analytical method with adequate selectivity, sensitivity, and reliability is essential for its quality control and therapeutic monitoring. A validated analytical method for the quantification of SRL was developed using High-Performance Liquid Chromatography coupled with a Diode Array Detector (HPLC-DAD). The method demonstrated linearity for SRL in the concentration range of 10 to 80 μg.mL⁻¹ (r = 0.9999). Precision was confirmed with coefficients of variation below 2%, and accuracy showed recovery values close to 100%. The validated method was successfully applied to sugar-coated tablets, demonstrating its suitability for routine quality control. Therefore, the developed method can be reliably used for the quantitative analysis of Sirolimus in sugar-coated tablets.